Taros YMCS Presentation Prize has been awarded in Portugal
The Taros YMCS Presentation Prize will be awarded
left: Fabrizio Giordanetto, PhD, Taros Chemicals
right: Duncan Hay, PhD, Evotec
The Taros YMCS Presentation Prize will be awarded to the best oral presentation at the EFMC Young Medicinal Chemist Symposium (EFMC-YMCS), including lectures by invited prize winners from national young medicinal chemist meetings in Europe and oral communications selected from submitted abstracts. The Prize consists of a diploma, € 1.000 and an invitation for a short presentation at an EFMC symposium.
Dortmund, Lisbon, 12.09.2014 ++++
This year’s YMCS Presentation Prize has been awarded to Duncan Hay.
Duncan Hay recently completed his DPhil, under the supervision of Prof. Chris Schofield at the University of Oxford and Dr Paul Brennan at the SGC. His thesis covered the design and synthesis of chemical probes for bromodomain containing proteins. Duncan received his MChem from the University of Edinburgh in 2003. From 2003-2011, he worked in Pfizer’s Discovery Chemistry labs at Sandwich, UK, working on various pre-clinical medicinal chemistry projects.
In 2014, Duncan joined Evotec, working as a Senior Scientist on a medicinal chemistry project at their site in Abingdon.
About Taros Chemicals
Taros is a privately owned discovery chemistry company, working with global pharmaceutical, biotech and chemical companies since 1999. Alongside our performance chemicals and material science division, Taros’ drug discovery mission is to create drug candidates as potential new medicines. Taros has a strong scientific track record on many biomolecular targets in all main therapeutic areas and thereby adding considerable value to collaborations from target validation and hit identification to lead generation and optimization. Taros’ core expertise ranges from custom synthesis and process development to modern medicinal and computational chemistry, as well as compound library design and production.
Taros was heading the chemistry efforts of the EUR 196 million funded European Lead Factory (2013-2018) and is currently heading its EUR 36.5 million funded continuation (2019-2022). Moreover, Taros is deeply engaged in other research alliances like the EUR 11 million funded Drug Discovery Hub Dortmund.
Youri R. Mesmoudi, Executive Vice President, e-mail: innovation |at| taros.de
As a leading contract research organization in discovery chemistry and custom synthesis, Taros provides comprehensive solutions to meet our clients’ needs from diverse branches and applications
Our experienced chemists practice a pragmatic culture and customer-centric approach in order to exceed project expectations, despite challenges, bridging very narrow timelines. They are trained to consider economic, safety and ecological boundaries and conditions laid out for all stages of the project, starting from the development of synthetic routes to…